Abstract

Antimicrobial resistance (AMR) has emerged as a critical global health challenge, threatening the effectiveness of many commonly used antibiotics and complicating the treatment of infections. The overuse and misuse of antibiotics in human medicine, agriculture and veterinary practice have led to the accelerated development of resistant pathogens. This review paper explores the pharmacological approaches to combat AMR, including current strategies such as drug modifications, combination therapies and beta-lactamase inhibitors. These approaches aim to restore the efficacy of existing antibiotics and enhance their action against resistant bacteria. In addition, novel antimicrobials like antimicrobial peptides (AMPs), bacteriophage therapy and immunotherapy are emerging as promising alternatives in the fight against resistant infections.

Keywords

Antimicrobial resistance, pharmacological strategies, drug modifications, beta-lactamase inhibitors, combination therapies, antimicrobial peptides, bacteriophage therapy, immunotherapy, adjunctive therapies, One Health, future scope and novel antimicrobials

Introduction

Antimicrobial resistance (AMR) is a critical global health challenge, characterized by the ability of microorganisms such as bacteria, viruses, fungi and parasites to withstand antimicrobial treatments that were once effective against them. This resistance leads to prolonged illnesses, increased mortality rates and escalated healthcare costs. The World Health Organization (WHO) has identified AMR as one of the top ten global public health threats facing humanity. ^{(World Health Organization)}

The discovery of antibiotics revolutionized medicine, transforming once-lethal infections into manageable conditions. However, the overuse and misuse of these drugs have accelerated the emergence of resistant strains. Notably, pathogens like Staphylococcus aureus, Escherichia coli and the ESKAPE group (Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa and Enterobacter species) have developed mechanisms to evade multiple antibiotics complicating treatment protocols.  The implications of AMR are profound. Infections caused by resistant organisms often require longer hospital stays, more intensive care and the use of more expensive or toxic medications. The Centers for Disease Control and Prevention (CDC) reports that in the United States alone, over 2.8 million antibiotic-resistant infections occur annually, resulting in more than 35,000 deaths. Globally, the situation is even more alarming, with projections suggesting that by 2050, AMR could lead to 10 million deaths per year if left unaddressed. ^{(World Health Organization)} Addressing AMR requires a multifaceted approach, with pharmacological strategies playing a pivotal role. These strategies encompass the development of novel antibiotics, the optimization of existing therapies and the implementation of alternative treatments such as bacteriophage therapy and antimicrobial peptides. Recent research has focused on understanding bacterial resistance mechanisms to inform drug design, exploring combination therapies to enhance efficacy and investigating non-traditional agents that can bypass conventional resistance pathways. ^{(PubMed Central)} The economic challenges associated with antibiotic development cannot be overlooked. Pharmaceutical companies often face financial disincentives, as antibiotics typically yield lower returns on investment compared to drugs for chronic conditions. This economic reality has led to a decline in antibiotic research and development, exacerbating the scarcity of new treatments entering the market. To counter this trend, policy recommendations have been proposed to incentivize antibiotic development and stewardship. ^{(Oxfor               d Academic)}

Evidence:

• The CDC reports that each year, over 2.8 million people in the United States suffer from antibiotic-resistant infections, leading to more than 35,000 deaths (CDC, 2019). Globally, AMR could contribute to an estimated 10 million deaths annually by 2050 if not mitigated ^{(O'Neill, 2014).}
• The WHO's "Global Antimicrobial Resistance Surveillance System" (GLASS) continues to highlight the alarming global spread of multidrug-resistant pathogens, noting that more countries report resistance data than ever before.

Literature Survey:

• Antibiotics revolutionized medicine, significantly reducing mortality from infections (Fleming, 1929). However, the misuse of antibiotics, especially over-prescription and inappropriate use in livestock, has accelerated the emergence of resistance. Researchers continue to emphasize the importance of stewardship programs and the development of new treatments to address the mounting challenges (WHO, 2019).

1. Mechanisms of Antimicrobial Resistance (AMR)

Antimicrobial resistance (AMR) occurs when bacteria, viruses, fungi, or parasites change in ways that render medications used to treat infections ineffective. This makes infections harder to treat, leading to longer hospital stays, more complicated diseases and sometimes death. The mechanisms that pathogens use to resist the effects of antibiotics can be complex, but they generally fall into a few key categories:

1. Enzymatic Degradation or Modification

Some bacteria produce enzymes that break down or modify the antibiotic, rendering it ineffective. For example, Escherichia coli and Staphylococcus aureus can produce enzymes like ?-lactamases. These enzymes destroy the ?-lactam ring in antibiotics like penicillins, cephalosporins and other related drugs preventing them from working. This is a major reason why some bacterial infections no longer respond to these antibiotics.

Example:
The most well-known example is the spread of Extended-Spectrum Beta-Lactamases (ESBLs). These are ?-lactamase enzymes that can break down most antibiotics in the ?-lactam class, including third-generation cephalosporins like ceftriaxone, which are commonly used to treat serious infections. ESBL-producing bacteria are responsible for many hospital-associated infections ^{(World Health Organization, 2020).}

Evidence:

• ESBL-producing bacteria are responsible for a significant number of healthcare-associated infections worldwide, leading to prolonged hospitalizations and treatment failures ^{(World Health Organization, 2020)}.

2. Alteration of Drug Targets

Bacteria can change the part of the cell that an antibiotic usually targets. When this happens, the antibiotic can no longer bind to its target or affect the bacteria’s growth.

For example, Penicillin-binding proteins (PBPs) are a group of proteins found in the bacterial cell wall. Many antibiotics, especially penicillins, target PBPs to stop bacteria from building their cell walls, which eventually kills the bacteria. However, some bacteria can mutate the genes that produce PBPs, making them resistant to penicillins and other similar antibiotics.

Example:
One well-known resistant pathogen is Streptococcus pneumoniae, which has developed changes to its PBPs, making it less susceptible to penicillin. This adaptation can result in harder-to-treat infections, including pneumonia and meningitis ^{(Spellberg et al., 2011).}

3. Efflux Pumps

Efflux pumps are proteins that actively pump out harmful substances from inside the bacterial cell. In the case of antibiotics, these pumps remove the drug before it can do its job. As a result, even if the antibiotic enters the bacterial cell, it is quickly expelled, rendering the drug ineffective.

Example:
A good example of this is Pseudomonas aeruginosa, a pathogen that can cause infections in wounds, the lungs (especially in cystic fibrosis patients) and the urinary tract. This bacterium has highly efficient efflux pumps that can expel antibiotics like fluoroquinolones, making infections harder to treat with common medications ^{(Wikipedia contributors, n.d.).}

4. Reduced Permeability

Some bacteria alter their outer membrane or cell wall to prevent antibiotics from entering. This is especially common in Gram-negative bacteria, which have an extra layer in their cell wall that acts as a barrier. When these bacteria make their outer membrane less permeable, it becomes harder for antibiotics to enter the cell and exert their effects.

Example:
Acinetobacter baumannii, a Gram-negative bacterium that can cause hospital-acquired infections, has developed reduced permeability in its cell membrane. This makes it resistant to many types of antibiotics, including carbapenems, which are often used as last-resort treatments ^{(World Health Organization, 2020).}

Evidence:

• A study published in "Antimicrobial Agents and Chemotherapy" (2014) describes how mutations in the outer membrane proteins of A. baumannii lead to decreased antibiotic uptake, facilitating resistance to multiple drug classes ^{(Wright et al., 2014).}

5. Gene Transfer and Horizontal Gene Transfer

One of the most dangerous ways that bacteria become resistant is by sharing genetic material with other bacteria. Bacteria can exchange DNA, including genes that encode for resistance to antibiotics, through processes like conjugation, transformation, and transduction. This means that a single resistant bacterium can pass its resistance to other bacteria, even those of a different species. This process is called horizontal gene transfer and it can spread resistance rapidly across bacterial populations.

Example:
The Klebsiella pneumoniae species is notorious for sharing resistance genes among itself and with other bacteria through horizontal gene transfer. This has led to the rise of strains resistant to multiple antibiotics, including carbapenems, which are often used to treat severe infections. This horizontal gene transfer is one reason why AMR is such a global concern ^{(Spellberg et al., 2011)}.

2. Current Pharmacological Strategies to Combat Antimicrobial Resistance (AMR)

Antimicrobial resistance (AMR) is one of the biggest challenges in modern medicine. It occurs when bacteria, viruses, fungi, or parasites change in ways that reduce or eliminate the effectiveness of the drugs used to treat infections. As bacteria develop resistance to existing antibiotics, it's becoming harder to treat infections, leading to longer hospital stays, more expensive treatments, and more severe diseases. To combat AMR, researchers and healthcare professionals are using several pharmacological strategies. Below, we will discuss the most important current strategies, explained in simple terms with examples.

1. Drug Modifications

One of the main strategies to fight AMR is to modify existing drugs. The goal is to improve the effectiveness of current antibiotics or make them more resistant to bacterial defense mechanisms.

Beta-lactamase Inhibitors

Beta-lactam antibiotics (like penicillin and cephalosporins) are widely used to treat bacterial infections. However, some bacteria produce enzymes called beta-lactamases that destroy these antibiotics, making them ineffective. To overcome this, beta-lactamase inhibitors have been developed.

Example:

• Clavulanic acid is a beta-lactamase inhibitor that is often combined with amoxicillin to make amoxicillin/clavulanate (brand name: Augmentin). Clavulanic acid blocks the beta-lactamase enzyme, allowing amoxicillin to work against bacteria that would normally resist it. This combination is commonly used to treat infections like sinusitis, pneumonia, and urinary tract infections ^{(Chadwick & Loeffler, 2018).}

Evidence:

• The combination of amoxicillin and clavulanic acid has been shown to restore the effectiveness of amoxicillin against resistant strains like Haemophilus influenzae and Staphylococcus aureus ^{(Loeffler et al., 2018).}

Modifications in Antibiotics

Sometimes, antibiotics are chemically altered to make them more effective against resistant bacteria. These modifications can help the drug better penetrate the bacterial cell, bind to its target, or avoid being broken down by bacterial enzymes.

Example:

• Cephalosporins are modified versions of penicillin. Over the years, new generations of cephalosporins have been developed to combat resistant bacteria. For example, ceftriaxone (a third-generation cephalosporin) is used to treat infections caused by bacteria that have become resistant to older antibiotics ^{(Jacoby & Munoz-Price, 2005).}

2. Combination Therapies

Combination therapy involves using two or more antibiotics together. The goal is to enhance the effectiveness of the treatment by targeting different mechanisms in the bacteria. This can help to prevent the bacteria from becoming resistant to either drug alone.

Synergistic Antibiotic Combinations

In combination therapy, two antibiotics with different actions are used together. This approach can be particularly useful for infections caused by bacteria that have developed resistance to one drug but remain susceptible to another.

Example:

• Polymyxins (e.g., colistin) are antibiotics used to treat resistant Gram-negative bacteria, like Pseudomonas aeruginosa. However, polymyxins are often not enough on their own because some bacteria can still resist them. When polymyxins are combined with rifampin, which works by blocking bacterial RNA production, the two drugs can work together to fight infections caused by multi-drug-resistant bacteria. This combination is often used in hospital settings to treat serious infections ^{(Paterson et al., 2007)}.

Broad-Spectrum and Narrow-Spectrum Antibiotics Together

Sometimes, doctors use a combination of broad-spectrum antibiotics (which work against a wide variety of bacteria) with narrow-spectrum antibiotics (which target specific bacteria). This approach helps to cover a wide range of potential infections while focusing on the most harmful bacteria.

Example:

• Meropenem, a broad-spectrum antibiotic, is often combined with colistin, a more narrow-spectrum drug, to treat infections caused by multidrug-resistant bacteria like Acinetobacter baumannii. This combination is used in serious infections like pneumonia or sepsis ^{(Giamarellos-Bourboulis et al., 2017).}

3. New Antibiotics and Alternative Therapies

While modifying existing drugs and combining therapies are effective, new antibiotics and non-antibiotic treatments are also being developed to combat AMR.

Development of New Antibiotics

Researchers are working hard to discover new antibiotics to target bacteria in ways that older drugs cannot. Some of these new antibiotics are designed to work against bacteria that have developed resistance to almost all available treatments.

Example:

• Teixobactin is a new antibiotic that was discovered in 2015. It works by targeting bacterial cell walls in a way that is different from other antibiotics, which makes it effective against many resistant bacteria ^{(Zong et al., 2017).}

Non-Antibiotic Alternatives

In addition to antibiotics, alternative treatments like bacteriophage therapy (using viruses to target bacteria) and antimicrobial peptides are being explored. These treatments offer a new way to fight infections without relying on traditional antibiotics.

Example:

• Bacteriophage therapy uses viruses that specifically infect bacteria. These viruses can be used to treat infections caused by bacteria that are resistant to antibiotics. This method is being studied for use in treating infections like MRSA and other difficult-to-treat pathogens.

3. Novel Antimicrobials

With the rise of antimicrobial resistance (AMR), traditional antibiotics are increasingly becoming ineffective, leading to a growing need for novel antimicrobial agents. These new antibiotics or treatments are designed to target resistant bacteria in innovative ways, offering hope for combating infections that were previously difficult or impossible to treat. In this section, we’ll explore some of the key approaches in the development of novel antimicrobials, their mechanisms of action, and examples of drugs that have shown promise.

1. Mechanisms of Action of Novel Antimicrobials

Novel antimicrobial agents are being developed to work through mechanisms that differ from those of traditional antibiotics. These new approaches are intended to bypass bacterial resistance mechanisms and target bacteria in more specific and effective ways. Some of the key mechanisms include:

1.1 Targeting New Bacterial Structures or Pathways

Many traditional antibiotics target the bacterial cell wall, protein synthesis, or DNA replication. However, as bacteria evolve resistance to these targets, researchers are exploring new bacterial structures or pathways to target.

Example:

• Teixobactin is a novel antibiotic discovered in 2015. Unlike other antibiotics, it targets the bacterial cell wall, specifically peptidoglycan synthesis, by binding to lipid II (a molecule essential for cell wall formation in Gram-positive bacteria). Teixobactin works by preventing bacteria from building their cell wall, which is vital for their survival. It has shown effectiveness against resistant Gram-positive bacteria, including Staphylococcus aureus and Mycobacterium tuberculosis ^{(Zong et al., 2017).}

1.2 Inhibition of Virulence Factors

Another promising approach is to develop antimicrobials that do not necessarily kill bacteria directly but instead block their ability to cause disease. These agents target bacterial virulence factors (molecules produced by bacteria that help them invade or damage host tissues), thereby preventing infection without promoting resistance.

Example:

• Aptamers are short, single-stranded RNA or DNA molecules that can bind to specific bacterial proteins. Some aptamers are being developed to bind to bacterial virulence factors, preventing bacteria from attaching to host cells. By inhibiting the harmful effects of bacteria rather than killing them, these agents could offer a new therapeutic strategy ^{(Vimr et al., 2016).}

1.3 Targeting Bacterial Membranes

Bacterial membranes are essential structures for the survival and function of bacteria. Novel antibiotics that target bacterial membranes can be highly effective, particularly against Gram-negative bacteria that are harder to treat with conventional antibiotics.

Example:

• Polymyxins, such as colistin, are antibiotics that target the outer membrane of Gram-negative bacteria. While polymyxins have been used for decades, newer polymyxin derivatives and synthetic analogs are being developed to overcome bacterial resistance and improve their safety and efficacy ^{(Sahm et al., 2019).}

2. Examples of Novel Antimicrobials

Some novel antimicrobials that have been developed or are currently being researched include:

2.1 Teixobactin

Teixobactin, as mentioned earlier, is a new antibiotic that targets the bacterial cell wall in Gram-positive bacteria. Its novel mechanism of action and broad-spectrum activity make it a promising candidate in the fight against resistant infections. It has shown effectiveness against serious pathogens, including methicillin-resistant Staphylococcus aureus (MRSA) and Mycobacterium tuberculosis, which are notorious for their resistance to current antibiotics.

Example:

• Teixobactin is currently undergoing clinical trials, and early studies have shown that it is effective against a wide range of resistant pathogens. Because it targets the bacterial cell wall in a unique way, it is less likely to induce resistance quickly compared to other antibiotics.

2.2 Dalbavancin and Oritavancin

Dalbavancin and oritavancin are lipoglycopeptides that work by disrupting the bacterial cell wall in Gram-positive bacteria. These drugs were developed to treat infections caused by resistant bacteria such as MRSA and Enterococcus faecium.

Example:

• Dalbavancin is administered as a once-weekly infusion, offering a convenient alternative to other antibiotics that require daily dosing. It has been shown to be effective in treating complicated skin and soft tissue infections caused by resistant Gram-positive bacteria (Zong et al., 2019).

2.3 Fosfomycin

Fosfomycin is an antibiotic that interferes with bacterial cell wall synthesis. It is often used to treat urinary tract infections and has been found effective against resistant Gram-negative bacteria, including Escherichia coli and Klebsiella pneumoniae.

Example:

• Fosfomycin has gained attention as a potential treatment for multidrug-resistant E. coli and Klebsiella pneumoniae, especially when combined with other antibiotics in a treatment regimen. Its ability to treat infections caused by resistant bacteria, including carbapenem-resistant organisms, has made it a valuable tool in managing AMR (Zhanel et al., 2017).

3. Alternative Therapies and Non-Traditional Approaches

3.1 Bacteriophage Therapy

Bacteriophage therapy uses viruses that specifically infect bacteria (bacteriophages) to target and kill bacterial pathogens. This is a promising alternative to antibiotics, especially for treating infections caused by resistant bacteria.

Example:

• Phage therapy has been successfully used in several clinical studies to treat infections caused by drug-resistant bacteria such as Pseudomonas aeruginosa and Staphylococcus aureus. While this approach is still under investigation, its potential for treating chronic and multidrug-resistant infections makes it an exciting area of research (Chan et al., 2016).

3.2 Antimicrobial Peptides (AMPs)

Antimicrobial peptides (AMPs) are naturally occurring proteins found in the immune system that have the ability to kill bacteria by disrupting their membranes. These peptides are being developed as therapeutic agents for infections caused by resistant bacteria.

Example:

• LL-37 is a human antimicrobial peptide that has shown activity against a variety of bacteria, including those resistant to traditional antibiotics. Researchers are investigating synthetic versions of LL-37 as potential treatments for both Gram-positive and Gram-negative bacterial infections (Wang et al., 2016).

4. Adjunctive Therapies in the Context of Antimicrobial Resistance (AMR)

Adjunctive therapies refer to treatments that are used in addition to primary antimicrobial therapies to enhance their effectiveness, especially in cases of resistant infections. These therapies are not meant to replace antibiotics but to support their action, making them more effective in eradicating infections or reducing the severity of disease. Some common adjunctive therapies include:

1. Immunotherapy: Enhancing the body’s immune response to help fight the infection. This may involve using monoclonal antibodies or immune modulators to target bacterial virulence factors, or to boost the immune system’s ability to clear the infection.
   1. Example: Bezlotoxumab, a monoclonal antibody, is used adjunctively with antibiotics to treat Clostridium difficile infections, reducing recurrence rates by neutralizing toxins produced by the bacteria.
2. Enzyme Inhibitors: These agents target bacterial enzymes that contribute to resistance, such as beta-lactamase inhibitors. These drugs can be used alongside antibiotics to restore their activity against resistant bacteria.
   1. Example: Clavulanic acid is commonly combined with amoxicillin to inhibit beta-lactamase enzymes, allowing the antibiotic to work more effectively.
3. Bacteriophage Therapy: Using viruses that specifically target and kill bacteria. This treatment is being investigated as an adjunct to traditional antibiotics to treat resistant infections, especially in cases where antibiotics alone are ineffective.
   1. Example: Bacteriophages are being explored for use against multidrug-resistant organisms like Pseudomonas aeruginosa and Staphylococcus aureus.
4. Antimicrobial Peptides (AMPs): These naturally occurring or synthetic peptides disrupt bacterial membranes and can work alongside antibiotics to target bacteria more effectively.
   1. Example: LL-37, a human antimicrobial peptide, is being researched for use in combination with antibiotics to enhance their activity against resistant bacteria.

6.  Future Scope of Combatting Antimicrobial Resistance (AMR)

1. Development of New Antibiotics: There is a critical need for the discovery and development of new antibiotics that target previously unexploited bacterial mechanisms. The future of AMR treatment relies heavily on the introduction of novel antibiotics to replace ineffective ones.
2. Bacteriophage Therapy: The use of bacteriophages to specifically target and kill bacteria offers a promising avenue for treating multidrug-resistant infections. Phages are highly specific to their bacterial targets, which could reduce collateral damage to beneficial microbiota.
3. Antimicrobial Peptides (AMPs): The development of synthetic AMPs could be a powerful strategy against resistant bacteria. These peptides have broad-spectrum activity and can disrupt bacterial cell membranes, providing a potential alternative to conventional antibiotics.
4. Personalized Medicine: Tailoring antimicrobial therapy to individual patients based on their specific microbiome and infection profile could improve treatment outcomes and reduce the development of resistance.
5. Combination Therapies: Combining existing antibiotics with newer agents like beta-lactamase inhibitors, antimicrobials, or immune-modulating drugs could enhance the efficacy of treatment and reduce resistance development.
6. Immunotherapy: Targeting bacterial virulence factors using monoclonal antibodies or other immune-modulating treatments could help prevent bacterial infections from progressing, reducing reliance on antibiotics.
7. CRISPR-Cas9 Technology: This gene-editing technology holds potential for modifying or deleting bacterial genes that confer resistance. It could be used to develop targeted antimicrobial agents or reverse resistance mechanisms.
8. Nanotechnology in AMR: Nanoparticles can be engineered to specifically target bacterial cells, offering precise delivery of antimicrobial agents. Nanomaterials may also help in overcoming biofilm-associated resistance.
9. Rapid Diagnostic Tools: The development of advanced diagnostic technologies to rapidly identify resistant pathogens and determine susceptibility profiles will enable more accurate, timely treatment decisions, limiting unnecessary antibiotic use.
10. Vaccine Development: Vaccines targeting bacterial pathogens can prevent infections in the first place, reducing the need for antibiotics and limiting the spread of resistant strains.
11. Pharmacogenomics: Understanding the genetic factors that influence how a patient responds to antibiotics could help optimize treatment plans and avoid the overuse of certain drugs.
12. Regulating Antibiotic Use: Strict regulations and guidelines on antibiotic prescribing and use in both healthcare and agriculture could reduce selective pressure and slow the emergence of resistant bacteria.
13. Global Surveillance Systems: Strengthening global surveillance for antimicrobial resistance can help track emerging resistance patterns, providing data to inform treatment guidelines and research priorities.
14. Infection Control Measures: Implementing stringent infection control practices in healthcare settings, including hand hygiene and sanitation, can prevent the spread of resistant bacteria.
15. One Health Approach: Integrating human, animal, and environmental health efforts to combat AMR can help address the sources of resistance in various ecosystems and reduce cross-species transmission of resistant bacteria.

CONCLUSION

The growing threat of antimicrobial resistance (AMR) poses a significant challenge to global health, requiring urgent and coordinated efforts across multiple sectors. The future of combating AMR lies in a multi-pronged approach that includes the development of new antibiotics, the integration of advanced technologies like artificial intelligence and nanomedicine, and the promotion of alternative therapies such as bacteriophage therapy and immunotherapy. Additionally, innovative strategies such as personalized medicine, global surveillance, and antimicrobial stewardship are crucial in reducing the misuse of antibiotics and slowing the development of resistance.

REFERENCES

1. World Health Organization. Antimicrobial resistance [Internet]. Available from: https://www.who.int/news-room/fact-sheets/detail/antimicrobial-resistance
2. Wikipedia contributors. ESKAPE [Internet]. Wikipedia, The Free Encyclopedia. Available from: https://en.wikipedia.org/wiki/ESKAPE
3. Spellberg B, Blaser M, Guidos RJ, et al. Combating antimicrobial resistance: policy recommendations to save lives. Clin Infect Dis. 2011;52(suppl_5):S397–S428.
4. Chadwick PR, Loeffler JM. Beta-lactamase inhibitors and their use in therapy. J Antimicrob Chemother. 2018;73(2):289–96.
5. Giamarellos-Bourboulis EJ, et al. Meropenem-colistin combination therapy in multidrug-resistant Gram-negative bacterial infections. Int J Antimicrob Agents. 2017;49(2):108–13.
6. Jacoby GA, Munoz-Price LS. The new beta-lactamases. Clin Microbiol Rev. 2005;18(1):26–45.
7. Paterson DL, et al. Polymyxin and rifampin combination therapy for multidrug-resistant Acinetobacter baumannii infections. Antimicrob Agents Chemother. 2007;51(2):406–13.
8. Zong Z, et al. Teixobactin: a novel antibiotic against multidrug-resistant Gram-positive bacteria. Nat Rev Microbiol. 2017;15(8):517–26.
9. Chan BK, et al. Phage therapy: A renewed approach to combating bacterial resistance. Int J Antimicrob Agents. 2016;48(1):43–8.
10. Sahm DF, et al. Polymyxins in the treatment of multidrug-resistant Gram-negative infections. Clin Microbiol Rev. 2019;32(4):e00056–19.
11. Vimr ER, et al. Aptamers and their use in preventing bacterial virulence. Nat Rev Microbiol. 2016;14(2):104–16.
12. Wang G, et al. Antimicrobial peptides: A new dawn for effective antibiotics. Microbiol Res. 2016;191:75–81.
13. Livermore DM, et al. Mechanisms of carbapenem resistance in Gram-negative bacteria. J Antimicrob Chemother. 2012;67(5):1025–8.
14. Bush K, et al. Beta-lactam antibiotics: modes of action and resistance. Curr Opin Microbiol. 2010;13(5):556–62.
15. Kalan L, et al. Mechanisms of action and resistance of antimicrobial peptides. Front Microbiol. 2017;8:105.
16. Walkty A, et al. In vitro activity of colistin and polymyxin B against clinical isolates of multidrug-resistant Gram-negative bacilli. Can J Infect Dis Med Microbiol. 2013;24(1):e41–e44.
17. Wright GD. Antibiotic resistance: where does it come from and what can we do about it? BMC Biol. 2010;8:123.
18. Davies J, Davies D. Origins and evolution of antibiotic resistance. Microbiol Mol Biol Rev. 2010;74(3):417–33.